Ghana

Population 2018: 30 million

<table>
<thead>
<tr>
<th>Tuberculosis profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimates of TB burden*, 2018</td>
</tr>
<tr>
<td>Total TB incidence</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
</tr>
</tbody>
</table>

 Estimated proportion of TB cases with MDR/RR-TB, 2018
- % tested with rapid diagnostics at time of diagnosis: 60%
- % with known HIV status: 93%
- % pulmonary: 92%
- % bacteriologically confirmed***: 66%
- % children aged 0-14 years: 6%
- % women: 30%
- % men: 64%
Total cases notified: 14,289

Universal health coverage and social protection
- TB treatment coverage (notified/estimated incidence), 2018: 32% (19–65)
- TB patients facing catastrophic total costs, 2016: 64% (61–68)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 39% (14–68)

Drug-resistant TB care, 2018
- % of bacteriologically confirmed TB cases tested for rifampicin resistance***: 93%
- Previously treated cases: 100%
Laboratory-confirmed cases*:
- MDR/RR-TB: 231
- XDR-TB: 0

Patients started on treatment* **:
- MDR/RR-TB: 147
- XDR-TB: 0

MDR/RR-TB cases tested for resistance to second-line drugs: 68

Treatment success rate and cohort size
- New and relapse: 86% 14,121
- Previously treated cases: 82% 429
- MDR/RR-TB cases started on second-line treatment in 2016: 62% 77
- XDR-TB cases started on second-line treatment in 2016: 0

TB preventive treatment, 2018
- % of HIV-positive people (newly enrolled in care) on preventive treatment: 77%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 30%

TB financing, 2019
- National TB budget (US$ millions): 20
- Funding source: 13% domestic, 47% international, 40% unfunded

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-10-25
Data: www.who.int/tb/data